Malaysia
Search
Sign In
Respirology
A smoking cessation intervention, introduced as part of lung health screening, may encourage quitting in about 30 percent of smokers, results of the UK-based YESS* trial showed.
A gut microbiota–derived synbiotic formula developed by researchers from the Chinese University of Hong Kong (CUHK) is shown in a randomized controlled trial to reduce the risk of bacterial and viral infections, including COVID-19, reduce the risk of adverse events (AEs) after COVID-19 vaccination, restore healthy gut microbiota, and provide other health benefits.
The addition of serplulimab to chemotherapy in the first-line setting improved overall survival (OS) in patients with extensive-stage small cell lung cancer (SCLC), according to results of the ASTRUM-005 trial.
Despite widespread uptake of vaccinations, COVID-19 remains a serious health issue for high-risk patients, owing to the emergence of new variants of concern (VOCs), waning immunity, and breakthrough infections.
At a recent symposium in Singapore, esteemed experts Dr Asok Kurup, Consultant Infectious Diseases Physician at Mount Elizabeth Medical Centre, Singapore, and Dr Alex Soriano, Head of Infectious Diseases Department, Hospital Clínic of Barcelona and Assistant Professor, University of Barcelona, Spain, gave insights on the evolution of global trends since the start of the COVID-19 pandemic and discussed key challenges in managing high-risk patients with COVID-19 in the ICU. They also highlighted early treatment strategies to minimize the burden of COVID-19 on healthcare systems.
A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.
Same-day pre-event screening for SARS-CoV-2 using antigen-detecting rapid diagnostic tests (Ag-RDT) may enable the resumption of large-scale indoor events which were halted or had their attendance capacity reduced during the COVID-19 pandemic, according to a study from Spain presented at ECCMID 2021.
A smoking cessation intervention, introduced as part of lung health screening, may encourage quitting in about 30 percent of smokers, results of the UK-based YESS* trial showed.
Adding nivolumab to paclitaxel-carboplatin chemotherapy in the neoadjuvant setting boosted progression-free survival (PFS) and overall survival (OS) in patients with resectable stage IIIA–B non-small cell lung cancer (NSCLC), according to results of the phase II NADIM II trial from Spain.
The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.
Bronchodilators, used in the treatment of chronic obstructive pulmonary disease (COPD), did not appear to benefit individuals with a history of smoking and respiratory symptoms who did not have airflow obstruction, results of the US-based RETHINC* study showed.
Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.
